ArticleTranslational cancer research2025
Development and validation of a necroptosis-related gene signature for predicting prognosis and immune infiltration in papillary thyroid cancer.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Papillary thyroid cancer (PTC) accounts for over 80-85% of all thyroid malignancies and presents a rising global incidence. Necroptosis plays a pivotal role in oncogenesis and immune regulation. However, the prognostic relevance of necroptosis-related genes (NRGs) in PTC remains inadequately explored. This study aims to construct a prognostic model for PTC based on NRGs and evaluate its predictive value for the prognosis of PTC patients. Methods: Using data from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO), prognostic-related genes (PRGs) were screened via univariate Cox analysis and subsequently refined using least absolute shrinkage and selection operator (LASSO) regularization. Gene set enrichment analysis (GSEA) was then performed for each identified prognostic gene. GSEA was conducted for each PRG, and immune characteristics were analyzed for patients stratified by risk scores. Potential therapeutic agents for PTC were also predicted. Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) was performed to evaluate messenger RNA (mRNA) and protein expression of PRGs in PTC samples. Results: Three PRGs ( Conclusions: A necroptosis-related prognostic signature composed of
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.